UAE How quickly can a country truly transform its healthcare system, while making it sustainable for the future? The mindset of Emiratis is that anything that is feasible and beneficial for the country should and will be done, regardless of the cost. This is why health authorities have been moving at…
Generics The Country President of AstraZeneca Philippines discusses the company’s new growth strategy, the need for affordable product pricing, and the growing knowledge initiatives the companies is producing in order to tackle the lack in qualified medical practitioners in the Philippines. When AstraZeneca’s global CEO Pascal Soriot took office late 2012,…
partnering David Setboun, Country President of AstraZeneca, discusses the opportunities that the Portuguese market can bring despite economic downturn, and the future of the Portuguese affiliate in expanding to new therapeutic areas. In what way do you think the pharmaceutical industry can act as an engine of economic recovery and development…
UAE Samer Al Hallaq, Gulf President of AstraZeneca, speaks about the company’s strategy to align its portfolio with the increasing presence of lifestyle diseases like diabetes, and how innovation is the driving force behind continued growth for the future. Let’s begin by speaking a little bit about AstraZeneca’s global focus…
Aspen Labs Marked socio-economic differences in Mexico are playing an important role in pushing the uptake of generics, and these issues are starting to affect multinational corporations (MNCs). MNCs are being forced to open up and diversify, quite simply to have their fingers in as many pies where they can compete successfully.…
Government Regulation You have been in Taiwan now for ten months. What are the most important characteristics of this market from your perspective, and what surprised you most about Taiwan? Taiwan is a highly developed economy to start with; it is a very established market, with a very good healthcare system. The…
Baltic You refer to AstraZeneca as the locomotive of bioscience in Sweden. Can you elaborate on what you mean by that, and the role that you see for AstraZeneca in pushing this development forward? AstraZeneca has a significant R&D presence in Sweden. We currently have more than 2,300 researchers at our…
AstraZeneca Australia You returned to Australia a year ago after spending eight years in Europe with the company. In your view, what were the key changes in the Australian market? Looking at the overall market, the biggest changes have been the various reforms to the Pharmaceutical Benefits Scheme (PBS). PBS reform started…
AstraZeneca Poland You have been quite recently appointed at the head of the Polish affiliate of AstraZeneca. With which personal ambitions did you come and what was the mission you were given when you took office? I would not say that I have been given a mission, but that I have been…
AstraZeneca Brazil What have been some of the recent milestones and achievements contributing to AstraZeneca Brazil’s status as the country’s fastest growing MNC? What happened in the last 10 years was a very productive combination of excellent products being worked by talented people with the right level of investment. This is what…
AstraZeneca Turkey Even though you have delivered strong results in most of the markets you have been appointed, this is your first assignment as the head of a subsidiary. For a man and manager who has experienced only successes in his life and career, what were the new challenges of leading a…
AstraZeneca Mexico There have been a lot of changes in the Mexican pharmaceutical industry in the last four to five years, most notably the new drug registration process being put in place. In your view, what have been the most significant changes, and how have they affected the market? The biggest shift…
See our Cookie Privacy Policy Here
